Article Per Year (5 Year)
p-Index From 2021 - 2026
1.383
P-Index
This Author published in this journals
All Journal Heca Journal of Applied Sciences Malacca Pharmaceutics Grimsa Journal of Science Engineering and Technology
Turalaki, Grace Lendawati Amelia
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Earth & Planetary Sciences Engineering Health Professions Immunology & microbiology Medicine & Pharmacology Physics

Published : 7 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Malacca Pharmaceutics

 1 
Targeting Prostate Cancer with Rambutan Peel-Derived Compounds via Network Pharmacology Utami, Wulandari Putri; Tallei, Trina Ekawati; Turalaki, Grace Lendawati Amelia; Tendean, Lydia Estelina Naomi; Kaseke, Martha Marie; Purwanto, Diana Shintawati
Malacca Pharmaceutics Vol. 3 No. 1 (2025): March 2025
Publisher : Heca Sentra Analitika

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.60084/mp.v3i1.262

Abstract

Prostate cancer is a prevalent malignancy in men, originating in the prostate gland and often driven by genetic alterations and hormonal dysregulation. Rambutan (Nephelium lappaceum L.) peel, a byproduct of fruit consumption, has demonstrated potential anticancer activity. This study employed a network pharmacology-based in silico approach to evaluate the therapeutic potential of rambutan peel extract in prostate cancer treatment. Bioactive compounds were identified through database searches, and their biological activities were predicted using PASS Online. Pharmacokinetic and toxicity profiles were assessed using ADMETLab 3.0 and Protox 3.0 to evaluate safety and drug-like properties. Potential target proteins were identified via SwissTargetPrediction and GeneCards, while protein-protein interaction networks were constructed using STRING. The pharmacological networks were visualized using Cytoscape to elucidate molecular mechanisms of action. The analysis identified 28 bioactive compounds in rambutan peel extract, with 11 demonstrating activity against prostate cancer (Pa > 0.5). These compounds were deemed safe based on Lipinski's Rule of Five (Ro5) and categorized within toxicity classes V and VI. Rambutan peel extract was found to target 501 proteins associated with prostate cancer, including key pathways involved in resistance to EGFR tyrosine kinase inhibitors. Network pharmacology analysis highlighted several key target genes, including SRC, GNAI1, PIK3CA, PIK3CD, MAPK1, MAPK3, AKT1, GNAI3, PRKCA, and HSP90AA1. Among these, SRC exhibited the highest centrality score, underscoring its pivotal role in disrupting tumorigenic and metastatic signaling pathways, suppressing cancer cell proliferation, and enhancing therapeutic responses. These findings suggest that rambutan peel extract holds promise as a natural therapeutic agent for prostate cancer, warranting further experimental and clinical validation.
Therapeutic Vaccines in Non-Small Cell Lung Cancer: Immunologic Mechanisms, Therapeutic Platforms, and Barriers to Efficacy Rumambi, Ekklesia Wulan Matilda; Tallei, Trina Ekawati; Turalaki, Grace Lendawati Amelia
Malacca Pharmaceutics Vol. 4 No. 1 (2026): March 2026
Publisher : Heca Sentra Analitika

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.60084/mp.v4i1.378

Abstract

Therapeutic vaccines for non-small cell lung cancer (NSCLC) aim to improve treatment outcomes for a disease with high global incidence, mortality, and recurrence risk despite receiving standard multimodal therapy. This field focuses on the use of cancer antigens as vaccine targets in the context of immunology, influenced by immunovigilance, immunoreduction, and the tumor microenvironment, which suppresses the immune system. Mechanistic requirements for effective vaccination include selecting cancer antigens that are highly and homogeneously expressed, functionally linked to oncogenic pathways, and efficiently presented via MHC molecules to coordinate T cell responses. Peptide-based, dendritic cell-based, nucleic acid-based, and microbial vector-based vaccine platforms demonstrate safety and induction of antigen-specific cellular immunity responses. However, survival remains moderate and inconsistent, particularly in advanced-stage patients. Future progress will depend on rigorous, mechanism-based design that integrates data-driven antigen and epitope selection with tailored platform and route selection to shape the desired immune response, while also facilitating personalized and optimized vaccination strategies.
Co-Authors Abas, Abdul Hawil Fatimawali . Kepel, Billy Johnson Laihad, Sarah Cecilia Astrid Martha Marie Kaseke Marunduh, Sylvia Ritta Niode, Nurdjannah Jane Purwanto , Diana Shintawati Purwanto, Diana Shintawati Rumambi, Ekklesia Wulan Matilda Runtunuwu, Stefanus Vicky Bernhard Elisa Setiono, Sabrina Brigitta Valerie Tallei , Trina Ekawati Tendean , Lydia Estelina Naomi Tendean, Lydia Estelina Naomi Tengke, Feniea Wulan Agaype TRINA EKAWATI TALLEI Utami, Wulandari Putri Wijaya, Puspita